Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1006Uterine Cervical Neoplasms 420Endometrial Neoplasms 350Carcinoma, Non-Small-Cell Lung 292Breast Neoplasms 292Neoplasms 238Colorectal Neoplasms 233Fallopian Tube Neoplasms 211Stomach Neoplasms 192Pancreatic Neoplasms 184Melanoma 157Prostatic Neoplasms 152Triple Negative Breast Neoplasms 148Carcinoma, Ovarian Epithelial 147Lung Neoplasms 136Neoplasm Metastasis 133Squamous Cell Carcinoma of Head and Neck 131Carcinoma, Renal Cell 130Head and Neck Neoplasms 122Esophageal Neoplasms 121Urinary Bladder Neoplasms 112Small Cell Lung Carcinoma 90Sarcoma 80Carcinoma, Hepatocellular 76Recurrence 70Carcinoma, Transitional Cell 70Uterine Cervical Dysplasia 66Papillomavirus Infections 66Colonic Neoplasms 59Cholangiocarcinoma 59

Interventions

Paclitaxel 1Gemcitabine 1Drug Evaluation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Serous Ovarian Cancer × Gynecologic × Clear all
NCT06055348 2023-09-26

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

Biocity Biopharmaceutics Co., Ltd.

Phase 1/2 Unknown
112 enrolled
Gynecologic

Serous Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡